Profusa, Inc., a commercial stage digital health company, announced the successful closing of its business combination with NorthView Acquisition Corp., a special purpose acquisition company. This transaction paves the way for Profusa's common stock to commence trading on Nasdaq under the ticker symbol "PFSA" starting July 14, 2025. The move marks a significant milestone in Profusa's mission to advance its pioneering tissue-integrating biosensors platform, designed for continuous biochemical monitoring and improved chronic disease management. The company expressed excitement about the potential impact of becoming a public entity on its ability to enhance healthcare solutions.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。